San Francisco startup Composition Therapeutics is additionally focusing on an oral, after-daily GLP-1 drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June any time a mid-phase review showed common weight loss of about six% and it plans to start out another mid-phase demo in the direction of the end of this calendar year�